###begin article-title 0
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Ca2+/Calmodulin-Dependent Kinase Kinase alpha Is Expressed by Monocytic Cells and Regulates the Activation Profile
###end article-title 0
###begin p 1
Conceived and designed the experiments: GF CG ED MH. Performed the experiments: CG ED MH JY. Analyzed the data: GF CG ED MH JY. Contributed reagents/materials/analysis tools: GF. Wrote the paper: GF CG ED MH KK.
###end p 1
###begin p 2
###xml 200 202 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 525 530 <span type="species:ncbi:9606">human</span>
Macrophages are capable of assuming numerous phenotypes in order to adapt to endogenous and exogenous challenges but many of the factors that regulate this process are still unknown. We report that Ca2+/calmodulin-dependent kinase kinase alpha (CaMKKalpha) is expressed in human monocytic cells and demonstrate that its inhibition blocks type-II monocytic cell activation and promotes classical activation. Affinity chromatography with paramagnetic beads isolated an approximately 50 kDa protein from nuclear lysates of U937 human monocytic cells activated with phorbol-12-myristate-13-acetate (PMA). This protein was identified as CaMKKalpha by mass spectrometry and Western analysis. The function of CaMKKalpha in monocyte activation was examined using the CaMKKalpha inhibitors (STO-609 and forskolin) and siRNA knockdown. Inhibition of CaMKKalpha, enhanced PMA-dependent CD86 expression and reduced CD11b expression. In addition, inhibition was associated with decreased translocation of CaMKKalpha to the nucleus. Finally, to further examine monocyte activation profiles, TNFalpha and IL-10 secretion were studied. CaMKKalpha inhibition attenuated PMA-dependent IL-10 production and enhanced TNFalpha production indicating a shift from type-II to classical monocyte activation. Taken together, these findings indicate an important new role for CaMKKalpha in the differentiation of monocytic cells.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 293 296 285 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Pace1">[1]</xref>
###xml 297 300 289 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 378 381 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 383 386 375 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Hathcock1">[4]</xref>
###xml 447 450 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 452 455 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Planelles1">[5]</xref>
###xml 457 460 445 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Iribarren1">[6]</xref>
###xml 609 612 597 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 614 617 602 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gerber1">[7]</xref>
###xml 682 685 670 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 738 741 722 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gerber1">[7]</xref>
###xml 858 861 842 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gerber1">[7]</xref>
###xml 863 866 847 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Anderson1">[8]</xref>
###xml 948 951 932 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 953 956 937 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tzachanis1">[9]</xref>
###xml 1008 1012 992 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rutschman1">[10]</xref>
###xml 1039 1043 1023 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Goerdt1">[11]</xref>
###xml 1054 1057 1038 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tzachanis1">[9]</xref>
###xml 1168 1172 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Schebesch1">[12]</xref>
###xml 1425 1428 1405 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gerber1">[7]</xref>
###xml 1430 1433 1410 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Anderson1">[8]</xref>
###xml 1435 1439 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Anderson2">[13]</xref>
###xml 1573 1577 1553 1557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Hesse1">[14]</xref>
###xml 1578 1582 1558 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gratchev1">[16]</xref>
Macrophages are capable of assuming numerous phenotypes depending on their microenvironment. Three broad categories of macrophage activation are-classical, type-II (innate) and alternative. Classical activation of macrophages results from exposure to IFNgamma followed by TNFalpha stimulation [1]-[3]. Classically activated macrophages increase their surface expression of CD86 [3], [4] and produce TNFalpha, IL-12, oxide radicals, and chemokines [3], [5], [6]. The ligation of the Fc receptors for IgG along with stimulation of Toll-like receptors, CD40, or CD44 results in type-II activation of macrophages [3], [7]. Type-II activated macrophages show enhanced expression of CD86 [3] and generate the cytokines TNFalpha, IL-1, and IL-6 [7]. These macrophages, however, also elaborate IL-10, which differentiates them from classically activated macrophages [7], [8]. The third type of activation, alternative activation, fails to up-regulate CD86 [3], [9] but does enhance macrophage production of arginase [10], IL-1 receptor antagonist [11] and IL-10 [9]. Interestingly, the activation of this pathway results in macrophages with a reduced ability to kill microbes [12] . Therefore, classical activation appears to initiate the inflammatory process through production of the pro-inflammatory cytokines TNFalpha, IL-1 and IL-6. Type-II activation likely modulates and/or reduces inflammation by inducing Th2 helper T-cells [7], [8], [13] while increasing synthesis of the anti-inflammatory cytokine IL-10. Alternative activation directs macrophages to a repair phenotype [14]-[16].
###end p 4
###begin p 5
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 348 350 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 361 365 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Hamilton1">[18]</xref>
###xml 366 370 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Buys1">[29]</xref>
###xml 398 400 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 427 431 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Smith1">[27]</xref>
###xml 433 437 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Smith2">[28]</xref>
###xml 522 526 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Lin1">[30]</xref>
###xml 555 557 551 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 572 574 568 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 611 615 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Soderling1">[31]</xref>
###xml 677 681 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Chin1">[32]</xref>
###xml 702 704 698 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 766 768 762 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 888 892 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu1">[33]</xref>
###xml 893 897 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu3">[36]</xref>
###xml 1100 1104 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Soderling1">[31]</xref>
###xml 1119 1121 1115 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1241 1245 1237 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Soderling1">[31]</xref>
Phorbol-12-myristate-13-acetate (PMA)-induced macrophage activation leads to increased expression of CD86 [17] indicating a classical or type-II activation phenotype. Importantly, studies employing PMA and calcium ionophores have linked IFNgamma-dependent macrophage activation to pathways requiring both protein kinase C (PKC) and intracellular Ca2+ elevation [18]-[29]. Increased intracellular Ca2+ following PMA stimulation [27], [28] is important as both a co-factor for the conventional PKC isoforms activated by PMA [30] and the activation of the Ca2+/calmodulin (Ca2+/CaM) pathway through binding to CaM [31]. CaM interacts with a wide array of kinases and phosphatases [32], most notably the Ca2+/calmodulin-dependent kinase (CaMK) cascade. Interestingly, Ca2+/CaM interaction with both CaMKs and the upstream kinase CaMK kinase (CaMKK) is required for activation of this pathway [33]-[36]. In addition to having a CaM binding domain (CBD) in common, each member of the CaMK cascade has a catalytic domain adjacent to a regulatory region containing an autoinhibitory domain (AID) and the CBD [31]. Binding of Ca2+/CaM to the CBD results in a conformation change in the AID that allows for substrate binding to the kinase in question [31].
###end p 5
###begin p 6
###xml 69 73 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Anderson2">[13]</xref>
###xml 75 79 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu4">[37]</xref>
###xml 128 132 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Sakagami1">[38]</xref>
###xml 150 154 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Soderling1">[31]</xref>
###xml 156 160 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Eto1">[39]</xref>
###xml 162 166 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Nakamura1">[40]</xref>
###xml 466 470 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu4">[37]</xref>
###xml 482 484 467 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 591 595 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Yano1">[41]</xref>
###xml 597 601 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Chen1">[42]</xref>
###xml 680 684 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Yano1">[41]</xref>
###xml 797 801 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Soderling1">[31]</xref>
###xml 803 807 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Sahyoun1">[43]</xref>
###xml 809 813 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Enslen1">[44]</xref>
###xml 894 898 871 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rousseau1">[45]</xref>
###xml 899 903 876 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Matsushita1">[47]</xref>
###xml 1207 1211 1172 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Wayman1">[46]</xref>
###xml 1213 1217 1178 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Matsushita1">[47]</xref>
###xml 1337 1341 1298 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu5">[48]</xref>
###xml 1435 1443 1396 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1448 1455 1409 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1455 1459 1416 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu5">[48]</xref>
###xml 1461 1465 1422 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu6">[49]</xref>
###xml 1810 1814 1767 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 1841 1846 <span type="species:ncbi:9606">human</span>
Two isoforms of CaMKK have been identified, CaMKKalpha and CaMKKbeta [13], [37], both of which have been found in the cytoplasm [38] and cell nucleus [31], [39], [40]. Prospective sequence analysis demonstrates that CaMKKalpha has a nuclear localization sequence (a.a. 456-474). The mechanics, however, behind subcellular localization of the CaMKKs in monocytic cells has not been previously investigated. CaMKKalpha has been shown to phosphorylate CaMKI and CaMKIV [37], mediate Ca2+-dependent protection from apoptosis during serum withdrawal through phosphorylation and activation of Akt [41], [42] and directly interact with serum and glucocorticoid-inducible kinase 1 (SGK1) [41]. As a result of the activation of CaMKIV, CaMKKalpha indirectly leads to the activation of ERK-2, JNK-1 and p38 [31], [43], [44]. In addition, CaMKKalpha can cross-talk with the adenylate cyclase/cAMP pathway [45]-[47]. In fact, this is one method for inhibiting CaMKKalpha activity, where treatment with forskolin, an adenylate cyclase activator, results in PKA activation and subsequent phosphorylation of CaMKKalpha on serine 458, within the CBD, and threonine 108, potentially involved in autoinhibition of CaMKKalpha [46], [47]. In addition, a direct means of CaMKKalpha inhibition was developed by Tokumitsu et al. with the generation of STO-609 [48]. STO-609 is an extensively studied selective inhibitor of CaMKKs, with little effect on PKCs in vitro and in vivo[48], [49]. Finally, little is known of CaMKK's biologic role outside of the central nervous system. We have previously demonstrated that PKCdelta translocation to the nucleus is associated with monocyte activation so we investigated the nuclear lysates of PMA activated U937 cells for proteins absent from nuclear lysates of non-PMA stimulated monocytes [17]. Here we demonstrate that human monocytic cells express CaMKKalpha, that expression of CD86, CD11b, TNFalpha, and IL-10 is regulated by CaMKKalpha and that inhibition of CaMKKalpha nuclear translocation is associated with blocking type-II monocytic cell activation and promoting classical activation.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
PMA induces CaMKKalpha nuclear localization
###end title 8
###begin p 9
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Weiel1">[23]</xref>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rovera1">[26]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Buys1">[29]</xref>
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo2">[50]</xref>
###xml 338 347 338 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1A</xref>
###xml 697 706 685 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1A</xref>
###xml 989 998 969 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1B</xref>
###xml 1220 1229 1196 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1C</xref>
Phorbol esters are potent stimulators of monocyte activation and have been used extensively to study macrophage differentiation [17]-[23], [26]-[29], [50]. In order to examine protein expression differences between nuclear lysates from PMA treated and non-PMA U937 cells, paramagnetic bead-assisted affinity chromatography was performed. Figure 1A shows that, when U937 cells were treated with PMA for 48 h, nuclear lysates from these cells contained an approximately 50 kDa protein that could be affinity isolated. Nuclear lysates from non-PMA treated cells did not contain this distinct band. To initiate identification of this protein, the approximately50 kDa silver stained band identified in Figure 1A was excised from the gel, trypsin-digested and mass mapped by MALDI-MS. Fragment analysis tentatively identified this protein as CaMKKalpha (GenBank accession number AF099105). Confirmation of this identification was performed by Western analysis using an anti-CaMKKalpha antibody (Figure 1B). Western analysis demonstrated that CaMKKalpha was recovered by affinity chromatography of nuclear lysates from PMA-treated cells while only traces were detected from nuclear lysates from non-PMA treated cells. Finally, Figure 1C demonstrates that CaMKKalpha was present in whole cell lysates of both PMA treated and untreated U937 cells. In addition, CaMKKbeta was not detected (data not shown). Taken together, these results confirm that CaMKKalpha is present in monocytic cells and indicates that it localizes to the nucleus of PMA stimulated cells.
###end p 9
###begin title 10
PMA induces CaMKKalpha nuclear localization.
###end title 10
###begin p 11
(A) U937 cells were treated with (+) or without (-) 100 nM PMA for 48 h and nuclear lysates were incubated with paramagnetic beads were as the solid phase. After extensive washing, proteins were resolved and visualized by SDS-PAGE and silver staining. Results are representative of three independent experiments. (B) U937 cells were treated and nuclear lysate affinity chromatography was performed as in panel A. CaMKKalpha mass was quantified by Western analysis. Results are representative of three independent experiments. (C) U937 cells were treated as in panel A. Affinity chromatography of whole cell lysates was performed as indicated. CaMKKalpha mass was quantified by Western analysis. Results are representative of three independent experiments.
###end p 11
###begin title 12
Inhibition of PKC decreases PMA-dependent up-regulation of CD86/CD11b expression
###end title 12
###begin p 13
###xml 126 137 126 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g002">Figure 2A&#8211;B</xref>
To determine the role of PKC in the PMA-induced CD86/CD11b expression, bisindolylmaleimide inhibition studies were performed. Figure 2A-B show that when U937 cells were pretreated with bisindolylmaleimide for 15 min prior to PMA stimulation for 48 h cell surface CD86/11b expression was inhibited by more than 75% when compared to PMA treatment alone (P<0.05). This finding indicates that PKC plays a critical role in modulating PMA-induced activation of costimulatory markers.
###end p 13
###begin title 14
The PKC inhibitor Bisindolylmaleimide inhibits PMA-dependent upregulation of CD86/CD11b expression.
###end title 14
###begin p 15
(A & B) U937 cells were pretreated with or without 1 microM bisindolylmaleimide for 15 min prior to activation with 100 nM PMA for 48 h, as indicated. Surface expression of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated CD86 antibodies. Results significantly different from PMA at alpha = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM.
###end p 15
###begin title 16
The CaMKKalpha inhibitor STO-609 enhances PMA-dependent up-regulation of CD86 but blocks CD11b expression and CaMKKalpha nuclear localization
###end title 16
###begin p 17
###xml 123 132 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3A</xref>
###xml 410 419 406 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3B</xref>
###xml 536 545 528 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3C</xref>
###xml 641 650 629 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1C</xref>
###xml 834 838 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 946 955 926 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3D</xref>
To determine the role of CaMKKalpha in PMA-dependent monocytic cell activation, STO-609 inhibition studies were performed. Figure 3A shows that, when U937 cells were pre-treated with STO-609 for 6 h prior to PMA addition for 48 h, cell surface CD86 expression was increased nearly 77% over PMA treatment alone (P<0.05). In contrast, STO-609 reduced PMA-dependent CD11b cell surface expression by 50% (P<0.05) (Figure 3B). Next, the consequence of STO-609 on PMA-dependent CaMKKalpha nuclear localization was examined. Western analysis (Figure 3C) demonstrated that STO-609 reduced CaMKKalpha nuclear localization by 50% (P<0.05). Similar to Figure 1C, PMA and/or STO-609 treatment had no impact on whole cell recovered CaMKKalpha (data not shown). Importantly, we have shown that ERK1/2 activation regulates CD86 and CD11b expression [17]. Interestingly, inhibition of CaMKKalpha with STO-609 had no impact on PMA-dependent activation of ERK1/2 (Figure 3D). These findings indicate that STO-609 inhibited PMA-induced up-regulation of CD11b and augmented PMA-stimulated CD86 expression. STO-609 also appears to inhibit PMA-dependent CaMKKalpha nuclear localization.
###end p 17
###begin title 18
The CaMKKalpha inhibitor STO-609 enhances PMA-dependent up-regulation of CD86 but blocks CD11b expression and CaMKKalpha nuclear localization.
###end title 18
###begin p 19
(A and B) U937 cells were pretreated with or without 5 microg/ml STO-609 for 6 h prior to activation with 100 nM PMA for 48 h, as indicated. Surface expression of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated CD86 antibodies. Results significantly different from PMA at alpha = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM. (C) Cells were treated as in panel A and CaMKKalpha was quantified by Western analysis of nuclear lysates. Results are representative of three independent experiments. (D) U937 cells were treated as in panel A and ERK1/2 phosphorylation (ERK-p) and mass (ERK) were measured by Western analysis in whole cell lysates. Results are representative of three independent experiments.
###end p 19
###begin title 20
Forskolin enhances PMA-dependent CD86 expression while inhibiting CD11b up-regulation and CaMKKalpha nuclear localization
###end title 20
###begin p 21
###xml 100 104 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Wayman1">[46]</xref>
###xml 106 110 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Matsushita1">[47]</xref>
###xml 316 320 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rousseau1">[45]</xref>
###xml 322 331 314 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4A</xref>
###xml 608 617 600 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4B</xref>
###xml 703 712 691 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4C</xref>
###xml 787 796 775 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1C</xref>
###xml 896 905 880 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4D</xref>
###xml 948 957 932 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3D</xref>
Activation of adenylate cyclase leads to PKA-dependent phosphorylation and inhibition of CaMKKalpha [46], [47]. To determine the impact of PKA-mediated inhibition of CaMKKalpha on PMA-dependent up-regulation of CD86 and CD11b, activation studies were performed with the potent adenylate cyclase activator, forskolin [45]. Figure 4A shows that, when U937 cells were pre-treated with forskolin for 1 h prior to PMA addition for 48 h, cell surface CD86 expression was increased 130% over PMA treatment alone (P<0.05). Conversely, forskolin decreased PMA-dependent CD11b cell surface expression by 50% (P<0.05) (Figure 4B). PMA-dependent nuclear localization of CaMKKalpha was examined by Western analysis (Figure 4C) and was reduced by 60% after forskolin pretreatment (P<0.05). Similar to Figure 1C, PMA and/or forskolin treatment had no impact on whole cell recovered CaMKKalpha (data not shown). Figure 4D demonstrates that forskolin like STO-609 (Figure 3D) had no impact on ERK1/2 phosphorylation or mass. These findings indicate that forskolin inhibits PMA-induced up-regulation of CD11b and augments PMA-stimulated CD86 expression. Forskolin, also appeared to inhibit PMA-dependent CaMKKalpha nuclear localization.
###end p 21
###begin title 22
Forskolin enhances PMA-dependent CD86 expression while inhibiting CD11b up-regulation and CaMKKalpha nuclear localization.
###end title 22
###begin p 23
(A and B) U937 cells were pretreated with or without 30 microM forskolin for 1 h prior to activation with 100 nM PMA for 48 h, as indicated. Surface expression of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated CD86 antibodies. Results significantly different from PMA at alpha = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM. (C) Cells were treated as in panel A and CaMKKalpha was quantified by Western analysis of nuclear lysates. Results are representative of three independent experiments. (D) U937 cells were treated as in panel A and ERK1/2 phosphorylation (ERK-p) and mass (ERK) were measured by Western analysis in whole cell lysates. Results are representative of three independent experiments.
###end p 23
###begin title 24
Inhibition of CaMKKalpha by siRNA enhances PMA-dependent up-regulation of CD86 but decreases CD11b expression
###end title 24
###begin p 25
###xml 132 141 128 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g005">Figure 5A</xref>
###xml 229 238 225 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g005">Figure 5B</xref>
###xml 456 465 448 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g005">Figure 5C</xref>
Inhibition of CaMKKalpha with siRNA followed by treatment with PMA, enhanced CD86 expression by 17% (P<0.05) compared to PMA alone (Figure 5A) while PMA-induced CD11b expression was reduced by 24% (P<0.05) compared to PMA alone (Figure 5B). CaMKKalpha knockdown did not significantly affect PMA independent CD86 expression or CD11b. The siRNA scrambled control sequence did not significantly alter CD86 or CD11b expression in any of the conditions tested. Figure 5C indicates that CaMKKalpha expression was decreased by nearly 76% by treatment with CaMKKalpha siRNA (P<0.05) while the siRNA scramble control did not significantly affect CaMKKalpha expression. Taken together, these data indicate that knockdown of CaMKKalpha expression alters PMA-induced macrophage differentiation.
###end p 25
###begin title 26
Inhibition of CaMKKalpha by siRNA enhances PMA-dependent up-regulation of CD86 but decreases CD11b expression.
###end title 26
###begin p 27
(A and B) Cells were treated with 0.25 microg of either CaMKKalpha siRNA or scramble siRNA control prior to stimulation with 100 nM PMA for 48 h. Surface expression of CD11b and CD86 was quantified by flow cytometry. Results significantly different from PMA at alpha = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM. (C) Cells were treated as in A and CaMKKalpha protein expression was quantified by intracellular flow. Results significantly different from control at alpha = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM.
###end p 27
###begin title 28
CaMKKalpha inhibition enhances PMA-induced production of TNFalpha while reducing that of IL-10
###end title 28
###begin p 29
###xml 125 128 117 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 249 258 237 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g006">Figure 6A</xref>
###xml 566 575 542 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g006">Figure 6B</xref>
Type-II activated macrophages produce both TNFalpha and IL-10 while classically activated macrophages generate just TNFalpha [3]. To determine if CaMKKalpha inhibition was important to macrophage cytokine production, cytokine assays were performed. Figure 6A demonstrates that PMA induced an increase in U937 cell TNFalpha production from 0 pg/ml to 764+/-22 pg/ml. STO-609 pre-treatment enhanced this response by 97% (P<0.05) while having no impact on basal TNFalpha production. U937 cell IL-10 elaboration was also increased by PMA from 0 pg/ml to 160+/-40 pg/ml (Figure 6B). In contrast to TNFalpha, STO-609 pre-treatment reduced IL-10 production by 70% (P<0.05). Production of the inflammatory cytokines IFN-gamma and IL-2 or the anti-inflammatory cytokines IL-5 and IL-4 were not detected (data not shown). Taken together, these data show that inhibition of CaMKKalpha reduces the production of IL-10 while enhancing that of TNFalpha indicating a shift from type-II to classical monocyte activation.
###end p 29
###begin title 30
CaMKKalpha inhibition enhances production of TNFalpha while reducing that of IL-10.
###end title 30
###begin p 31
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
(A and B) U937 cells (1x106 cells/treatment) were pretreated with or without 5 microg/ml STO-609 for 6 h prior to activation with 100 nM PMA for 48 h, as indicated. TNFalpha and IL-10 concentrations were quantified from culture supernatants by cytokine assays. Results significantly different from PMA at alpha  = 0.05 are indicated by (*). Results represent an average of three independent experiments+/-SEM.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 170 174 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Uchi1">[51]</xref>
###xml 378 387 378 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1A</xref>
###xml 681 690 661 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1B</xref>
###xml 859 868 831 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1C</xref>
###xml 917 926 889 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g001">Figure 1B</xref>
The co-stimulatory molecule, CD86, is expressed on both classical and type-II activated macrophages and is necessary to define a classically activated macrophage [3]. We [17] and others [51] have previously shown that during monocytic cell activation CD86 up-regulation requires ERK1/2. Up-regulation, however, of CD86 during type-II activation has not been thoroughly studied. Figure 1A shows that a prominent approximately50 kDa band was affinity purified from nuclear lysates derived from PMA-activated U937 cells. Combining MALDI-MS fragment analysis with subsequent Western analysis using a CaMKKalpha specific antibody, a component of this band was identified as CaMKKalpha (Figure 1B). Next, CaMKKalpha was isolated from whole cell lysates of both PMA treated and untreated U937 cells. Importantly, PMA did not increase CaMKKalpha mass in whole cells (Figure 1C) or nuclear lysates from non-PMA treated cells (Figure 1B). Taken together, these data indicate that PMA-dependent activation of monocytic cells is associated CaMKKalpha nuclear translocation. Importantly, the identification of this enzyme in the U937 cell line may provide new avenues for the treatment of monocytic cell leukemia. Indeed, the potential of CaMKKs as therapeutic targets is currently being investigated by our laboratory.
###end p 33
###begin p 34
###xml 138 142 138 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Stout1">[52]</xref>
###xml 327 331 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 413 417 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Huang1">[53]</xref>
###xml 591 602 587 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g002">Figure 2A&#8211;B</xref>
###xml 860 864 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu5">[48]</xref>
###xml 974 986 962 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figures 3A&#8211;B</xref>
###xml 1086 1095 1070 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3C</xref>
###xml 1249 1253 1229 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Sakagami1">[38]</xref>
###xml 1254 1258 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Nakamura1">[40]</xref>
###xml 1409 1413 1389 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 1471 1475 1447 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Enslen1">[44]</xref>
###xml 1572 1581 1540 1549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3D</xref>
###xml 1683 1685 1651 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1712 1716 1680 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Lin1">[30]</xref>
###xml 1718 1722 1686 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Fukuda1">[54]</xref>
###xml 1723 1727 1691 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-MacNeil1">[56]</xref>
Given the central role of monocytes in the immune response and the importance of coordinating activation in specialized microenvironments [52] we investigated the effect of PMA stimulation on CD86/CD11b expression. We have previously shown that PKCdelta plays a critical role in IL-4 mediated PMA-induced CD86/CD11b expression [17], however, prolonged exposure to PMA has been shown to down-regulate certain PKCs [53] so we preformed experiments to investigate the effects of PKC inhibition. Treatment with bisindolylmaleimide significantly attenuated PMA-induced CD86 and CD11b expression (Figure 2A-B) indicating that activation of PKCs was essential to PMA-induced CD86 and CD11b expression. Next, in order to determine if CaMKKalpha regulated CD86 expression, CD86 expression was examined in PMA-activated U937 cells. Inhibition of CaMKKalpha with STO-609 [48] increased PMA-dependent CD86 expression nearly 77% while PMA-induced CD11b expression was attenuated by 50% (Figures 3A-B). STO-609 also impaired the translocation of CaMKKalpha into the nucleus following PMA-activation (Figure 3C). This is consistent with the hypothesis that activation of CaMKKalpha may lead to nuclear targeting of this protein and initiation of downstream events [38]-[40]. ERK1/2 is critical to activation-dependent monocytic cell CD86 expression. We have shown that CD86/CD11b expression after activation requires ERK1/2 [17]. Notably, CaMKKalpha can lead to the activation of ERK-2 [44]. To determine if CaMMKalpha regulated ERK1/2, STO-609 inhibition of CaMMKalpha was utilized. As Figure 3D shows, PMA-dependent ERK1/2 activation was not enhanced or decreased by STO-609. While the PKC and Ca2+/CaM pathways can interact [30], [54]-[56], our data may represent that under strong MAPK stimulation, via PMA-PKC, the phosphorylation of ERK by CaMK is redundant and consequently inhibition of CaMKK is without effect.
###end p 34
###begin p 35
###xml 127 131 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rousseau1">[45]</xref>
###xml 272 276 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Wayman1">[46]</xref>
###xml 278 282 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Matsushita1">[47]</xref>
###xml 454 458 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Rousseau1">[45]</xref>
###xml 460 472 444 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figures 4A&#8211;B</xref>
###xml 667 671 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 676 685 660 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4D</xref>
###xml 962 971 942 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4C</xref>
###xml 1030 1039 1010 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">Figure 4D</xref>
###xml 1082 1090 1062 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figure 3</xref>
###xml 1171 1175 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Tokumitsu5">[48]</xref>
Work by Wayman et al. and Matsushita et al. demonstrated that forskolin inhibits CaMKKalpha activity by inducing PKA-dependent [45] phosphorylation of serine 458, within the CaMKKalpha calmodulin binding domain, and threonine 108, involved in autoinhibition of CaMKKalpha [46], [47]. To investigate the impact of a second mechanism of CaMKKalpha inhibition on PMA-induced CD86/CD11b expression, we used forskolin, a potent activator of adenylate cyclase [45]. Figures 4A-B demonstrates that forskolin, itself, does not impact CD86 or CD11b expression. This result was expected because we have shown that PMA dependent-up-regulation of CD86 requires ERK1/2 activation [17] and Figure 4D demonstrates that forskolin alone did not activate ERK1/2. However, when forskolin was used in conjunction with PMA, a doubling of CD86 expression and an attenuation of CD11b up-regulation was observed. Additionally, CaMKKalpha nuclear translocation was blocked by forskolin (Figure 4C), while PMA-stimulated ERK-1/2 activation was unaffected (Figure 4D). These effects mimicked that of STO-609 (Figure 3), an inhibitor of CaMKKalpha that works through an entirely different mechanism [48]. Although the use of two pharmacological inhibitors of CaMKKalpha that act through different mechanisms provides strong evidence that CaMKKalpha regulates PMA-induced CD86 and CD11b expression, direct molecular interventions provide the strongest evidence. When CaMKKalpha expression was reduced by siRNA knockdown, PMA-dependent CD86 expression was enhanced and CD11b expression decreased as expected. Taken together, these findings indicate that CaMKKalpha is an important regulator of macrophage differentiation.
###end p 35
###begin p 36
###xml 21 23 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 219 221 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 252 254 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 275 279 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Klein1">[19]</xref>
###xml 366 368 362 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 368 372 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Smith2">[28]</xref>
###xml 608 612 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Engels1">[57]</xref>
###xml 711 713 707 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 719 723 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Skelton1">[58]</xref>
###xml 746 748 742 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 869 871 865 867 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 994 998 990 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Somers1">[21]</xref>
###xml 1000 1004 996 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Celada1">[22]</xref>
###xml 1135 1137 1131 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1167 1171 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Karimi1">[59]</xref>
###xml 1233 1235 1229 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1286 1290 1282 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Moon1">[60]</xref>
###xml 1306 1310 1302 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Keenan1">[61]</xref>
###xml 1330 1334 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Moses1">[62]</xref>
###xml 1388 1390 1384 1386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1594 1596 1590 1592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1621 1623 1617 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1636 1640 1632 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-MacNicol1">[63]</xref>
###xml 1802 1806 1794 1798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 1995 1997 1975 1977 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2068 2072 2048 2052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mellor1">[64]</xref>
###xml 2264 2273 2232 2241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g003">Figures 3</xref>
###xml 2274 2275 2242 2243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g004">4</xref>
###xml 104 110 <span type="species:ncbi:10090">murine</span>
###xml 303 309 <span type="species:ncbi:10090">murine</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 640 645 <span type="species:ncbi:9606">human</span>
###xml 1089 1094 <span type="species:ncbi:9606">human</span>
###xml 1316 1321 <span type="species:ncbi:10090">mouse</span>
PMA activates both Ca2+-dependent and -independent events within the cell. Specific surface proteins on murine macrophages such as HLA-DR and FcgammaR are increased in response to PMA, which is dependent on increased Ca2+, but is not affected by the Ca2+/CaM or PKC pathways [19]. Cellular spreading of murine macrophages in response to PMA requires intracellular Ca2+[28], treatment of malignant myeloid progenitor cells from patients with chronic myelogenous leukemia with a calcium ionophore leads to expression of CD86 and other surface markers including those for dendritic cell-activation and adhesion [57], and expression of CD86 in human monocyte-derived dendritic cells is also increased by elevated Ca2+ flux [58]. However, increased Ca2+ is not always the critical factor in PMA-mediated effects. In the case of macrophage priming, increased intracellular Ca2+ alone is not sufficient and stimulation with activators of PKCs, such as PMA, is needed to achieve priming of these cells [21], [22]. Arachadonic acid release and IgG-mediated phagocytosis following PMA activation of human monocytes occurs through activating a Ca2+-independent phospholipase A2 [59], potentially mediated by PKC. In addition, PMA has defined Ca2+-independent effects in glomerular mesangial cells [60], T lymphocytes [61], and mouse oocytes [62]. Therefore, we examined the impact of ionomycin, a Ca2+-ionophore, on PMA-induced CD86 expression and found no effect of ionomycin alone or in combination with PMA (data not shown). This indicates that increased CD86 expression requires more than increased Ca2+ and activation of the Ca2+/CaM pathway [63]. We have also shown that inhibition of PMA-dependent activation of PKCdelta markedly augments CD86 expression while blocking CD11b expression in monocytic cells [17]. This effect was correlated with loss of PKCdelta activation and failure of PKCdelta to translocate to the nucleus. PKCdelta is classified as a novel isoform in that it does not require Ca2+ but is dependent on diacylglycerol and phosphatidyserine for activity [64]. Therefore, one possibility to account for CaMKKalpha nuclear translocation is via an association with PKCdelta. Since activation of CaMKKalpha appears to be important for nuclear targeting (Figures 3-4) interaction with PKCdelta could represent a critical step in this regulatory process, although further evidence is needed to establish such a relationship.
###end p 36
###begin p 37
###xml 267 270 263 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Mosser1">[3]</xref>
###xml 317 321 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Opal1">[65]</xref>
###xml 323 327 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Strle1">[66]</xref>
###xml 474 477 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Gerber1">[7]</xref>
###xml 701 713 689 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001606-g006">Figures 6A&#8211;B</xref>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
Finally, an important distinction between classically activated macrophages and type-II activated macrophages is the type of cytokines produced. Both forms of activation result in the production of TNFalpha, however IL-10 is only elaborated during type-II activation [3]. IL-10 is a potent anti-inflammatory cytokine [65], [66] and Gerber et al. demonstrated that IL-10 was necessary for the ability of type-II activated macrophages to rescue mice from a lethal dose of LPS [7]. Therefore, we examined the production of these two cytokines following monocytic cell activation and found that inhibition of CaMKKalpha caused a 97% increase in TNFalpha production and a 70% decrease in IL-10 production (Figures 6A-B). Taken together these results indicate that PMA induces a type-II activation profile and that CaMKKalpha inhibition shifts the activation state to the classical pathway. Importantly, our data demonstrate a new role for CaMKKalpha in macrophage differentiation, and indicate an association between the inhibition of CaMKKalpha and its nuclear translocation.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
Materials
###end title 39
###begin p 40
###xml 150 153 <span type="species:ncbi:9685">cat</span>
###xml 262 265 <span type="species:ncbi:9685">cat</span>
###xml 383 386 <span type="species:ncbi:9685">cat</span>
###xml 452 455 <span type="species:ncbi:9685">cat</span>
###xml 550 553 <span type="species:ncbi:9685">cat</span>
###xml 655 661 <span type="species:ncbi:9986">rabbit</span>
###xml 870 873 <span type="species:ncbi:9685">cat</span>
###xml 960 963 <span type="species:ncbi:9685">cat</span>
###xml 1000 1003 <span type="species:ncbi:9685">cat</span>
###xml 1070 1073 <span type="species:ncbi:9685">cat</span>
The monocytic cell line U937 was purchased from American Type Culture Collection (Manassas, VA). SuperSignal(R) West Pico chemiluminescent substrate (cat. #34077) was purchased from Pierce (Rockford, IL). NitroBind(R), Pure nitrocellullose membrane 0.45 microm (cat. #EP4HYB0010) was purchased from Osmotics (Westborough, MA). Fluorescein isothiocyanate (FITC)-conjugated anti-CD86 (cat. #MHCD8601-4), and R-Phycoerythrin (PE-R)-conjugated anti-CD11b (cat. #MHCD11b04) were purchased from Caltag (Burlingame, CA). Anti-phospho-ERK1/2- Thr202/Tyr204 (cat. #9106) was purchased from Cell Signaling Technology (Beverly, MA). Anti-CaMKKalpha(sc-11370) , anti-rabbit IgG-FITC antibody (sc-2012), CaMKKalpha siRNA (sc-29904), Control siRNA (sc-37007) and siRNA transfection reagent (sc-29528) was purchased from Santa Cruz Biotechnology (Santa Cruz, California). Anti-ERK1/2 (cat. #06182) was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Forskolin (cat. #344270), and Bisindolylmaleimide (cat. #203293) were purchased from Calbiochem (La Jolla, CA). STO-609 (cat. #1551) was purchased from Tocris Cookson, Inc. (Ellisville, MO). All other cell culture reagents and chemicals were purchased from Sigma (Saint Louis, MO).
###end p 40
###begin title 41
Cell Culture
###end title 41
###begin p 42
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 80 86 <span type="species:ncbi:9913">bovine</span>
U937 cells were cultured in growth media (RPMI 1640 supplemented with 10% fetal bovine serum, 2.0 g/L sodium bicarbonate, 2.5g/L glucose, 100,000 units/L penicillin, and 100 mg/L streptomycin, 1 mM sodium pyruvate and 10 mM HEPES, pH 7.4) as previously described [17]. Cells were passaged 1:2 with fresh medium every three days. For all experiments, cells were washed twice and re-suspended in growth media at 1x106 cells/ml with the indicated treatments.
###end p 42
###begin title 43
CaMKKalpha Knockdown
###end title 43
###begin p 44
siRNA knockdown of CaMKK was performed according to the manufacturer's instructions. In brief, cells were cultured in antibiotic free media for 24 h washed twice and resuspended in 200 microl transfection media containing 0.25 microg of siRNA duplex (scrambled control or CaMKKalpha cocktail) and 2 microl of siRNA transfection reagent. Cells were incubated as described above for 6 h, then 500 microl of fresh transfection media was added and cells incubated for an additional 24 h. Finally, cells were washed and resuspended in growth media and treated with PMA for 48 h and assayed by flow cytometry. CaMKKalpha expression was quantified by intracellular flow cytometry.
###end p 44
###begin title 45
Nuclear Lysates
###end title 45
###begin p 46
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 182 183 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
were isolated as previously described [17]. 1x106 cells/test were stimulated as indicated and then washed with ice-cold DPBS, spun and resuspended in Buffer A (10 mM KCl, 1.5 mM MgCl2, 1 mM dithiothreitol (DTT), 1 microg/ml leupeptin, 1 microg/ml aprotinin, 1 mM PMSF and 10 mM HEPES, pH 7.9). After 15 min on ice, lysates were passed through a 26(1/2) gauge needle three times and then centrifuged at 800xg for 10 min at 4degreesC. The nuclear pellet was re-suspended in Buffer A and layered over a 30% sucrose cushion (w/v in Buffer A) and centrifuged 15 min at 5000xg at 4degreesC. The purified nuclear pellet was then incubated in 25% glycerol, 400 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1 microg/ml leupeptin, 1 microg/ml aprotinin and 10 mM HEPES, pH 7.9 with vortexing for 30 min at 4degreesC. After centrifugation at 16,000xg for 30 min at 4degreesC, the supernatant (nuclear extract) was analyzed
###end p 46
###begin title 47
Whole cell Lysates
###end title 47
###begin p 48
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo1">[17]</xref>
###xml 58 59 58 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
were prepared as previously described [17]. In brief, 1x106 cells/test were lysed in 1 ml of ice-cold lysis buffer (1% Triton X-100, 150 mM NaCl, 1 mM NaF, 1 mM EGTA, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 microg/ml aprotinin, 2 microg/ml leupeptin, 1 mM sodium orthovanadate and 50 mM Tris-base, pH 7.4) by double passage through a 26(1/2)-gauge needle. Lysates were cleared by centrifugation at 16,000xg for 10 min.
###end p 48
###begin title 49
Paramagnetic Bead Affinity Chromatography
###end title 49
###begin p 50
###xml 61 83 61 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cellular Fractionation</italic>
###xml 709 710 690 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
U937 cell nuclear or whole cell lysates, generated as above (Cellular Fractionation), were diluted to 1 microg/ml with Buffer A (without Triton X-100) to ensure adequate column absorption and flow. Lysates and paramagnetic beads (Miltyni, Auburn, CA) were then incubated together at 21degreesC for 5min. Bead complexes were washed extensively with 10 mM KCl, 7% glycerol, 1 mM DTT, 10 mM HEPES, pH 7.9. Columns were then eluted with 1% SDS, 1 mM DTT, 10 mM Tris-HCl, pH 6.8, and proteins separated on 10% polyacrylamide gels. Gels were either electro-transfered to nitrocellulose for Western analysis or silver stained using the SilverQuesttrade mark kit (Invitrogen, Carlsbad, CA). For silver staining, 15x106 cells/test were used.
###end p 50
###begin title 51
Mass Spectrometry (MS)
###end title 51
###begin p 52
###xml 925 931 <span type="species:ncbi:9796">equine</span>
Proteins were separated by SDS-PAGE and silver stained using SilverQuest (Invitrogen) following manufactures instructions. Silver stained bands were excised, de-stained (following manufactures instructions) and speed vacuum-dried until tacky. Gel pieces were rehydrated in 100 mM ammonium bicarbonate with 2 microg/ml trypsin and incubated at 37degreesC for 36 h. Trypsin digestion was stopped by addition of 10% trifluoroacetic acid (TCA) and peptides extracted into 50 microl of 10% TCA/60% acetonitrile. Samples were then concentrated by 1/3 via speed vacuum drying and further concentrated and desalted via strong cation exchange using ZipTip (Millipore) packed with SCX resin (Millipore). Peptide molecular ions were analyzed in the positive ion mode using a Voyager 4066 Mass Spectrometer (Applied Biosystems) where acceleration voltage was set at 20 kV and 100 laser shots were summed. To calibrate peptide digestion, equine myoglobin was used as an external standard. PeptIdent (Swiss Institute of Bioinformatics) was used to identify the monoisotope peptide masses where 1 missed cleavage was allowed and a minimum of 4 matching peptides was required for a match. The pI range was +/-2.00 and the molecular weight range was +/-20%.
###end p 52
###begin title 53
Flow Cytometry
###end title 53
###begin p 54
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo2">[50]</xref>
###xml 379 380 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 561 562 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 821 827 <span type="species:ncbi:9913">bovine</span>
###xml 1109 1115 <span type="species:ncbi:9913">bovine</span>
was performed as previously described [50]. In brief, after indicated treatments, cells were incubated in growth media supplemented with 5 mM EDTA for 1 hr at 37degreesC and then washed once in 0.5% Dulbecco's phosphate-buffered saline (DPBS) containing 0.5% BSA (DPBS-BSA) without calcium and magnesium. Fluorochrome-conjugated antibodies at 10 microg/ml/test were added to 1x106 cells and incubated on ice for 15 min and then washed with DPBS-BSA 0.5% Fluorescence was detected on an Epics XL flow cytometer (Beckman Coulter, Fullerton, CA) quantifying 1.5x104 events using gates to exclude nonviable cells as determined by propidium iodide staining. For intracellular staining, cells were fixed in 2% formalin/PBS for 10 m at room temperature, washed twice with DPBS-BSA 0.5% and blocked with PBS containing 10% fetal bovine serum for 20 m. 100 microl of PBS/FBS containing 0.2 % triton and 10 ug/ml/test of CaMKKalpha antibody or isotype control was added and cells were allowed to incubate overnight at 4degreesC. Cells were then washed twice with DPBS-BSA 0.5% and blocked with PBS containing 10% fetal bovine serum for 20 m. 100 microl of PBS/FBS containing 0.2 % triton and 10 ug/ml/test anti-IgG-FITC detection antibody was added cells were allowed to incubate for 1 h at room temperature then washed twice with DPBS-BSA 0.5%. Fluorescence was detected as above. Cell viability for all experiments was at least 85%. Median values of each population were used to indicate the levels of expression of each antigen assayed.
###end p 54
###begin title 55
Western analysis
###end title 55
###begin p 56
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001606-Deszo2">[50]</xref>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
was performed as previously described [50]. Proteins were resolved by SDS-PAGE (1x106 cells/lane) in 10% gels and then electro-transferred to nitrocellulose. Immunoreactive proteins were visualized with the indicated primary antibodies using enhanced chemiluminescence (ECL) (Amersham) followed by densitometry.
###end p 56
###begin title 57
Cytokine Assays
###end title 57
###begin p 58
###xml 304 305 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 409 411 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rd</sup>
Measurement of IL-10, IL-4, TNF-alpha, IL-2, IL-5 and IFN-gamma were performed using the Cytometric Bead Array Kit (BD PharMingen) as per the manufacturer's instructions. Fluorescence was detected on a Cytomation MoFlo flow cytometer (DakoCytomation Colorado Inc, Fort Collins, Colorado) quantifying 5x104 events. Absolute cytokine amounts were calculated by comparison to a standard curve generated using a 3rd order polynomial regression curve-fitting algorithm. Limits for detection were IL-10 (2.8 pg/ml), IL-4 (2.6 pg/ml) TNF-alpha (2.8 pg/ml), IL-2 (2.6 pg/ml), IL-5 (2.4 pg/ml) and IFN-gamma (7.1 pg/ml).
###end p 58
###begin title 59
Statistical Analysis
###end title 59
###begin p 60
Where indicated, experimental data was analyzed by the Student's t-test for comparison of medians using Microsoft Excel (Redmond, WA).
###end p 60
###begin p 61
We thank Dr. Michael Lasker and Dolores Doane for their review of this manuscript and Dr. Barbara Pilas and Ben Montez with the Keck Biotechnology Center Flow Cytometry Facility for their help conducting flow cytometry experiments.
###end p 61
###begin title 62
References
###end title 62
###begin article-title 63
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.
###end article-title 63
###begin article-title 64
###xml 125 142 <span type="species:ncbi:5693">Trypanosoma cruzi</span>
Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism.
###end article-title 64
###begin article-title 65
The many faces of macrophage activation.
###end article-title 65
###begin article-title 66
Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function.
###end article-title 66
###begin article-title 67
###xml 95 112 <span type="species:ncbi:5693">Trypanosoma cruzi</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Differential CD86 and CD40 co-stimulatory molecules and cytokine expression pattern induced by Trypanosoma cruzi in APCs from resistant or susceptible mice.
###end article-title 67
###begin article-title 68
Activation of macrophages by silicones: phenotype and production of oxidant metabolites.
###end article-title 68
###begin article-title 69
Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors.
###end article-title 69
###begin article-title 70
A novel phenotype for an activated macrophage: the type 2 activated macrophage.
###end article-title 70
###begin article-title 71
Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses.
###end article-title 71
###begin article-title 72
Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production.
###end article-title 72
###begin article-title 73
Alternative versus classical activation of macrophages.
###end article-title 73
###begin article-title 74
Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro.
###end article-title 74
###begin article-title 75
Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta.
###end article-title 75
###begin article-title 76
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.
###end article-title 76
###begin article-title 77
###xml 93 98 <span type="species:ncbi:9606">human</span>
Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts.
###end article-title 77
###begin article-title 78
Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3.
###end article-title 78
###begin article-title 79
IL-4-dependent CD86 expression requires JAK/STAT6 activation and is negatively regulated by PKCdelta.
###end article-title 79
###begin article-title 80
###xml 56 62 <span type="species:ncbi:10090">murine</span>
Interferon-gamma modulates protein kinase C activity in murine peritoneal macrophages.
###end article-title 80
###begin article-title 81
Role of intracellular calcium concentration and protein kinase C activation in IFN-gamma stimulation of U937 cells.
###end article-title 81
###begin article-title 82
###xml 60 66 <span type="species:ncbi:10090">murine</span>
IFN-gamma potentiates the accumulation of diacylglycerol in murine macrophages.
###end article-title 82
###begin article-title 83
###xml 47 53 <span type="species:ncbi:10090">murine</span>
Phorbol esters and calcium ionophore can prime murine peritoneal macrophages for tumor cell destruction.
###end article-title 83
###begin article-title 84
Role of protein kinase C and intracellular calcium mobilization in the induction of macrophage tumoricidal activity by interferon-gamma.
###end article-title 84
###begin article-title 85
###xml 94 100 <span type="species:ncbi:10090">murine</span>
Biochemical models of gamma-interferon action: altered expression of transferrin receptors on murine peritoneal macrophages after treatment in vitro with PMA or A23187.
###end article-title 85
###begin article-title 86
###xml 77 83 <span type="species:ncbi:10090">murine</span>
gamma-Interferon enhances the secretion of arachidonic acid metabolites from murine peritoneal macrophages stimulated with phorbol diesters.
###end article-title 86
###begin article-title 87
Mechanism of calcium ionophore A23187-induced priming of bone marrow-derived macrophages for tumor cell killing: relationship to priming by interferon.
###end article-title 87
###begin article-title 88
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester.
###end article-title 88
###begin article-title 89
The role of calcium in macrophage chemotaxis to the phorbol ester tumor promoter TPA.
###end article-title 89
###begin article-title 90
###xml 59 65 <span type="species:ncbi:10090">murine</span>
Calcium modulation of phorbol ester-induced alterations in murine macrophage morphology.
###end article-title 90
###begin article-title 91
Fusion of intracellular membrane pools with cell surfaces of macrophages stimulated by phorbol esters and calcium ionophores.
###end article-title 91
###begin article-title 92
Distinct PKC isoforms mediate the activation of cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages.
###end article-title 92
###begin article-title 93
The Ca-calmodulin-dependent protein kinase cascade.
###end article-title 93
###begin article-title 94
Mechanisms for regulation of calmodulin kinase IIalpha by Ca(2+)/calmodulin and autophosphorylation of threonine 286.
###end article-title 94
###begin article-title 95
Requirements for calcium and calmodulin in the calmodulin kinase activation cascade.
###end article-title 95
###begin article-title 96
Calcium/calmodulin-dependent protein kinase kinase: identification of regulatory domains.
###end article-title 96
###begin article-title 97
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase.
###end article-title 97
###begin article-title 98
Regulatory mechanism of Ca2+/calmodulin-dependent protein kinase kinase.
###end article-title 98
###begin article-title 99
Characterization of a Ca2+/calmodulin-dependent protein kinase cascade. Molecular cloning and expression of calcium/calmodulin-dependent protein kinase kinase.
###end article-title 99
###begin article-title 100
###xml 123 126 <span type="species:ncbi:10116">rat</span>
Distinct immunohistochemical localization of two isoforms of Ca2+/calmodulin-dependent protein kinase kinases in the adult rat brain.
###end article-title 100
###begin article-title 101
###xml 54 76 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Ca(2+)/Calmodulin-dependent protein kinase cascade in Caenorhabditis elegans. Implication in transcriptional activation.
###end article-title 101
###begin article-title 102
###xml 77 80 <span type="species:ncbi:10116">rat</span>
Distribution of Ca2+/calmodulin-dependent protein kinase kinase alpha in the rat central nervous system: an immunohistochemical study.
###end article-title 102
###begin article-title 103
Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway.
###end article-title 103
###begin article-title 104
Inhibition of interleukin-1beta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88.
###end article-title 104
###begin article-title 105
Phosphorylation of a Ras-related GTP-binding protein, Rap-1b, by a neuronal Ca2+/calmodulin-dependent protein kinase, CaM kinase Gr.
###end article-title 105
###begin article-title 106
Regulation of mitogen-activated protein kinases by a calcium/calmodulin-dependent protein kinase cascade.
###end article-title 106
###begin article-title 107
Ca(2+)-dependent sensitization of adenylyl cyclase activity.
###end article-title 107
###begin article-title 108
Inhibitory cross-talk by cAMP kinase on the calmodulin-dependent protein kinase cascade.
###end article-title 108
###begin article-title 109
Inhibition of the Ca2+/calmodulin-dependent protein kinase I cascade by cAMP-dependent protein kinase.
###end article-title 109
###begin article-title 110
STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase.
###end article-title 110
###begin article-title 111
A single amino acid difference between alpha and beta Ca2+/calmodulin-dependent protein kinase kinase dictates sensitivity to the specific inhibitor, STO-609.
###end article-title 111
###begin article-title 112
CD45 negatively regulates monocytic cell differentiation by inhibiting phorbol 12-myristate 13-acetate-dependent activation and tyrosine phosphorylation of protein kinase Cdelta.
###end article-title 112
###begin article-title 113
CX-659S, a diaminouracil derivative, indirectly inhibits the function of Langerhans cells by blocking the MEK1/2-Erk1/2 pathway in keratinocytes.
###end article-title 113
###begin article-title 114
Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences.
###end article-title 114
###begin article-title 115
Differential down-regulation of protein kinase C isozymes.
###end article-title 115
###begin article-title 116
Role of the calcium-calmodulin system in the adenylate cyclase activity of vascular smooth muscle.
###end article-title 116
###begin article-title 117
Relationship among calmodulin-, forskolin-, and guanine nucleotide-dependent adenylate cyclase activities in cerebellar membranes: studies by limited proteolysis.
###end article-title 117
###begin article-title 118
Calmodulin regulation of adenylate cyclase activity.
###end article-title 118
###begin article-title 119
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells.
###end article-title 119
###begin article-title 120
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose.
###end article-title 120
###begin article-title 121
Protein kinase C activation precedes arachidonic acid release during IgG-mediated phagocytosis.
###end article-title 121
###begin article-title 122
Phorbol esters potentiate tyrosine phosphorylation of epidermal growth factor receptors in A431 membranes by a calcium-independent mechanism.
###end article-title 122
###begin article-title 123
###xml 50 55 <span type="species:ncbi:9606">human</span>
Protein kinase C isotypes theta, delta and eta in human lymphocytes: differential responses to signalling through the T-cell receptor and phorbol esters.
###end article-title 123
###begin article-title 124
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
Calcium-independent, meiotic spindle-dependent metaphase-to-interphase transition in phorbol ester-treated mouse eggs.
###end article-title 124
###begin article-title 125
Cross-talk between protein kinase C and multifunctional Ca2+/calmodulin-dependent protein kinase.
###end article-title 125
###begin article-title 126
The extended protein kinase C superfamily.
###end article-title 126
###begin article-title 127
Anti-inflammatory cytokines.
###end article-title 127
###begin article-title 128
Interleukin-10 in the brain.
###end article-title 128
###begin p 129
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 129
###begin p 130
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by grants from the National Institutes of Health (DK064862 to G.G.F, NS046227 to M.E.H., Ruth Kirschstein Institutional National Research Service Award 5T32 DK59802 to the Division of Nutritional Sciences and Predoctoral Fellowship to C.B.G.), University of Illinois Agricultural Experiment Station (to G.G.F.).
###end p 130

